Condition Focus: Osteoarthritis — Macrophage-Chondrocyte Cross-Talk and Cartilage Protection
This 2025 study represents some of the most sophisticated methodology applied to understanding PBM’s joint-protective effects. Using a combination of single-cell RNA sequencing (scRNA-seq), in vivo OA mouse models (destabilisation of the medial meniscus), and macrophage-chondrocyte co-culture experiments, the researchers demonstrated that PBM protects cartilage not by acting on chondrocytes directly, but by shifting macrophages from the destructive M1 phenotype to the protective M2 phenotype.
The identified pathway — IL-6/JAK/STAT — explains how M1 macrophages damage cartilage: they produce IL-6, which activates the JAK/STAT signalling cascade in chondrocytes, driving them toward a catabolic (breakdown) rather than anabolic (building) state. PBM interrupts this cross-talk by reducing M1 macrophage numbers (CD86+ cells decreased) while increasing M2 macrophages (CD206+ cells increased), thereby reducing the IL-6 signal that drives cartilage destruction.
The scRNA-seq data adds particular weight: rather than measuring a handful of pre-selected markers, single-cell sequencing captures the entire transcriptional landscape of every cell in the tissue sample, providing unbiased confirmation that the macrophage phenotype shift is real and comprehensive.
For gout, this macrophage-chondrocyte cross-talk is directly relevant. During repeated gout flares, M1 macrophages in the joint produce IL-6 that damages cartilage over time. By shifting these macrophages to M2, PBM may not only resolve the acute flare but also protect against the chronic cartilage damage that accumulates with recurrent gout.
G.O.A.T. for Gout Alignment:
The macrophage-chondrocyte cross-talk identified here represents a dual benefit of PBM: acute flare resolution (M1→M2 shift) and long-term cartilage protection (reduced IL-6-mediated catabolism). The G.O.A.T.’s maintenance dosing protocol may support this chronic protective effect.
Link to original research here
Editor’s note: The IL-6/JAK/STAT pathway identified here complements the PI3K/AKT/mTOR pathway in Tian et al 2023. The cartilage-protective implications connect to the direct chondrocyte evidence in Oliveira et al 2025 and the proteoglycan restoration in Balbinot et al 2021. For the comprehensive M1→M2 evidence base, see M1→M2 Polarization Review 2025.
Related Articles
- PBM Increases M2 Macrophages via PI3K/AKT/mTOR at 980nm – Tian et al 2023
- NIR PBM Stimulates Cartilage Matrix Synthesis in Human Chondrocytes – Oliveira et al 2025
- PBM Restores Cartilage Integrity and Reduces Chronic Pain in OA – Balbinot et al 2021
- PBM and Macrophage Polarization: M1→M2 Shift Review – 2025
- PBM Modulates Macrophage via Notch1-HIF-1α-NF-κB: RNA-seq – Ma et al 2022
Key Takeaways
- PBM protects cartilage by shifting macrophages M1→M2 — reducing IL-6-driven chondrocyte catabolism
- IL-6/JAK/STAT pathway identified as the macrophage-chondrocyte cross-talk mechanism
- scRNA-seq provides unbiased, whole-transcriptome confirmation of the phenotype shift
- Dual benefit: acute flare resolution (M1→M2) + long-term cartilage protection (IL-6↓)
Study Overview
| Study Type: | Animal + in vitro + bioinformatics (multi-method) |
| Wavelength(s): | Not specified in abstract |
| Treatment Protocol: | DMM-induced OA mouse model; macrophage-chondrocyte co-culture |
| Sample Size: | Mouse groups + in vitro co-culture + scRNA-seq analysis |
| Primary Outcome: | CD86↓ (M1), CD206↑ (M2); IL-6/JAK/STAT pathway; chondrocyte catabolism↓ |
Full Citation
PBM mitigates chondrocyte catabolism in osteoarthritis by regulating macrophage M1 polarization through the IL-6/JAK/STAT signaling pathway. (2025). Journal of Orthopaedic Surgery and Research, 20. View Publication
